Sanofi, Regeneron: Dupilumab Hits Main Objectives In Late Stage Asthma Trial

Lisensi Anda Salah atau Anda belum memasukkan Lisensi

Source : http://www.nasdaq.com/press-release/sanofi-regeneron-dupilumab-hits-main-objectives-in-latestage-asthma-trial-20170911-00012

Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
Sanofi Management Discusses Q4 2013 Results - Earnings Call Transcript
Regeneron, Sanofi asthma drug data fails to excite investors
Sanofi and Regeneron score asthma hit with dupilumab
Sanofi: Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
Sanofi, Regeneron: Dupilumab Meets Main Objectives In Late-Stage Asthma Trial